Survival analysis demonstrated that high levels of ERα, ERβ, or EGFR were significantly correlated with worse 10-year overall survival for the late-stage NSCLC patients (Fig. 5c). The gene discussed is ESR2; the disease is non-small cell lung carcinoma.